ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2755

Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients

Ahmed Omar1, Laura Passalent2, Renise Ayearst3, Ismail Sari1, Anthony V. Perruccio4, Rajiv Gandhi5, Nigil Haroon1 and Robert D Inman1, 1Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 2Allied Health, Toronto Western Hospital, Toronto, ON, Canada, 3Medicine, University Health Network, Toronto, ON, Canada, 4Health Care & Outcomes Research, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Department of Surgery - Orthopedics, Toronto Western Hospital, Assistant Professor, Department of Surgery, University of Toronto​, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS), AS, geriatrics, spondylarthritis and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Data on disease characteristics of geriatric patients (>=65 years) with AS are lacking. The objective of this study is to compare: 1) the clinical profile of geriatric and non-geriatric patients with AS and 2) geriatric AS patients with aged-matched non-AS comparators.

Methods: Data were extracted from a Toronto based longitudinal SpA cohort. Patients with AS were divided by current age into geriatric (age >= 65 years) and non-geriatric (age < 65 years) groups. Clinical and laboratory data were then compared. Data for the non-AS geriatric age-matched control group was obtained from a Toronto tertiary care orthopedics clinic.

Results: There were 48 geriatric AS patients out of 890 AS patients in the clinic (table 1). 322 knee OA patients were included for the non-AS geriatric comparison (table 2). Initial comparison (young vs geriatric AS), showed no differences in sex distribution. Age at time of diagnosis was higher in the geriatric AS patients (p<0.001). In terms of clinical activity, there was no difference in mean inflammatory markers or BASDAI scores. Extra-articular manifestations were similar. There was no significant difference between the 2 groups regarding the usage of NSAIDs, DMARDS, corticosteroids and biologics, nor in their side-effects. Only 1% of the geriatric group started biologic therapy at age >=65 yr. Infection frequency was similar between the two groups. Mobility (BASMI) and function (BASFI) scores were higher in the geriatric group (p<0.001 and 0.04 respectively). The geriatric group were more likely to have a history of physical trauma/ injury (p=0.03). The SF-36 mental component was also higher in the geriatric group. Quality of life scores were similar. Comparison of geriatric AS and geriatric OA patients revealed more males in the AS group. Non-AS patients are more likely to be smokers and have a history of diabetes (p=0.04). Functional disability scores were also higher.

Conclusion: We show that geriatric AS patients have reassuringly similar treatment and disease activity parameters, but differed in a select few functional components and comorbidities when compared to the younger population. The younger population was diagnosed earlier than the elder group, which may reflect better disease awareness among physicians over the last few years. When compared to geriatric non-AS controls, there was a higher prevalence of females, diabetes and smokers in the non-AS geriatric patients. Further research into the geriatric AS population is needed to better define and manage their specific needs, especially as this patient population will be substantial in the coming years.

Table 1 Geriatric (age >= 65 years) N=48 Non geriatric AS (age < 65 years) N=842 p value
Male (%) 83.33 72.21 0.23
HLA-B27 positive (%) 64.58 70.78 0.35
Age at last visit (years) 70.6 ±5.25 41.2 ±12.06 <0.001
Age at time of diagnosis (years) 43.5 ±16.79 29.99 ±11.19 <0.001
Age at symptom onset (years) 35.21 ±16.46 23.39 ±9.28 <0.001
Disease duration at last clinic visit (years) 27.23 ±17.87 11.32 ±9.68 <0.001
Unemployed due to disability from AS (%) 8.33 12.95 0.35
Responsive to NSAIDs (ever) 75.0 68.63 0.16
NSAIDS ever 77.08 82.19 0.37
NSAID at last visit 56.10 53.12 0.70
NSAID related side effects (%) 25.00 25.18 0.97
DMARD use (%) ever 22.92 27.20 0.51
DMARD related side effects (%) 2.08 8.08 0.13
Current glucocorticoid use (%) (oral steroids) 25.86 16.58 0.06
Oral Steroid related side effects (%) 0 1.19 0.44
Biologic use (ever) (%) 39.58 51.19 0.11
Biologic at last visit 54.17 66.93 0.19
Biologic related side effects (%) 12.50 15.20 0.61
AS patients who started on Biologics after 65 5 (1%)    
CRP 9.84 ±10.56 10.39 ±12.36 0.73
ESR 14.68 ±12.05 13.16 ±13.19 0.40
BASDAI 4.26 ±1.98 4.29 ±2.25 0.92
BASMI 4.95 ±2.17 2.50 ±2.32 <0.001
BASFI 4.79 ±2.81 3.42 ±2.86 0.04
SF-36 mental component 55.39 ±10.19 46.51 ±11.99 0.01
SF-36 physical component 38.40 ±8.58 41.00 ±39.38 0.35
Fatigue severity scale 5.19 ±2.76 4.94 ±2.64 0.59
ASQoL 6.64 ±5.16 6.99 ±5.52 0.68
Peripheral arthritis – ever (%) 79.17 65.68 0.05
Dactylitis – ever (%) 2.08 1.54 0.77
Enthesitis – ever (%) 16.67 24.47 0.21
Uveitis – ever (%) 43.75 31.95 0.08
Psoriasis – ever (%) 8.33 11.05 0.55
IBD – ever (%) 8.33 11.52 0.49
Smoking (ever) (%) 33.33 30.40 0.66
Physical trauma or injury (ever) 29.17 16.98 0.03
Hypertension (ever) 70.83 13.42 <0.001
Diabetes (ever) 6.25 3.92 0.42
Angina (ever) 6.25 1.90 0.04
MI (ever) 0 1.43 0.40
Congestive heart failure (ever) 2.08 0.12 0.005
Infection (ever) 35.42 30.64 0.48
COPD (ever) 6.25 2.02 0.05
Asthma (ever) 4.17 7.48 0.39
CVA (ever) 4.17 0.36 0.006
Neuropathy (ever) 14.58 5.70 0.01
Stomach/Duodenal ulcer (ever) 6.25 7.84 0.68
Depression (ever) 18.75 10.57 0.07
Osteoporosis (ever) 12.50 4.39 0.01
HAQ (last visit) 0.99 ±0.73 0.80 ±0.63 0.08
Overall HAQ score 0.77 ±0.64 0.65 ±0.52 0.22
Dressing/shoe laces 0.89 ±0.79 0.75 ±0.72 0.24
Stand up from chair 0.79 ±0.81 0.75 ±0.68 0.75
Cane (ever) 22.92 10.69 0.009
Walker (ever) 12.50 2.26 <0.001
Crutches (ever) 6.25 0.95 0.001

 

Table 2: Geriatric AS (age >= 65 years) N=48 Geriatric OA controls (age >= 65 years) N=322 p value
Gender male (%) 83.33 44.10 <0.001
Age 70.59 ±5.25 69.18 ±6.42 0.09
Unemployment due to disability 8.33 4.97 0.33
Smoking 33.33 50.31 0.02
Diabetes 6.25 17.78 0.04
MI 0 6.65 0.06
Heart Failure 2.08 0.32 0.12
Lung disease (Asthma, COPD) 10.42 7.05 0.40
History of Stomach/ Duodenal  ulcer 6.25 5.10 0.73
Depression 18.75 15.11 0.51
Dress yourself/ socks on or off 0.89 ±0.79 1.76 ±1.03 <0.001
Stand up from chair 0.79 ±0.81 2.23 ±0.96 <0.001
Get in out bed 0.71 ±0.66 1.85 ±0.97 <0.001
Walk on flat ground 0.55 ±0.56 1.90 ±0.91 <0.001
Climb steps 0.66 ±0.81 2.50 ±0.91 <0.001
  *Continuous variables were presented as mean ±SD for both tables

Disclosure: A. Omar, None; L. Passalent, None; R. Ayearst, None; I. Sari, None; A. V. Perruccio, None; R. Gandhi, None; N. Haroon, None; R. D. Inman, None.

To cite this abstract in AMA style:

Omar A, Passalent L, Ayearst R, Sari I, Perruccio AV, Gandhi R, Haroon N, Inman RD. Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparison-of-clinical-profile-of-geriatric-and-non-geriatric-ankylosing-spondylitis-as-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-profile-of-geriatric-and-non-geriatric-ankylosing-spondylitis-as-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology